NCT06188676View on ClinicalTrials.gov

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

PHASE3RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

April 1, 2029

Study Completion Date

April 1, 2029

Conditions

Primary Mediastinal Lymphoma

Interventions

DRUG

Cyclophosphamide

Ciclofosfamida

DRUG

Doxorubicin Hydrochloride

Adriamycin

DRUG

Etoposide Phosphate

Etopophos

DRUG

Prednisolone

Prednisolonum

DRUG

Rituximab

Chimeric Anti-CD20 Antibody

DRUG

Vincristine Sulfate

Oncovin

DRUG

Filgrastim

G-CSF

DRUG

Pegfilgrastim

PEG-filgrastim

DRUG

Nivolumab 40 mg in 4 ml Injection

Opdivo

Trial Locations (1)

125167

RECRUITING

National Research Center for Hematology, Moscow

All Listed Sponsors

lead

National Research Center for Hematology, Russia

NETWORK